HGH Fragment 176-191 vs Tirzepatide
A side-by-side research comparison of HGH Fragment 176-191 and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | HGH Fragment 176-191 | Tirzepatide |
|---|---|---|
| Full name | Human Growth Hormone Fragment 176-191 | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | Mimics lipolytic action of HGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing cyclic AMP and hormone-sensitive lipase activity. Does not affect IGF-1. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 1,817 Da | 4,814 Da |
| Half-life | 3-4 hours | 5 days (120 hours) |
| Bioavailability | High (SubQ) | High (SubQ ~80%) |
| Typical dose | 250-500 mcg | 2.5 mg → titrate up to 15 mg |
| Frequency | 1-2x daily | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
HGH Fragment 176-191 reported benefits
- Targeted fat loss
- No IGF-1 elevation
- No glucose impairment
- No bone/organ growth effects
- Improved body composition
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.